Self-Assembled Protein Particles for CD8-T Cell Responses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine formulations face challenges in effectively inducing both innate and adaptive immune responses, particularly with soluble proteins having limited ability to be presented in the major histocompatibility complex type I, and there is a need for alternative approaches to provide effective immunogens that can induce specific CD8-T cell cytotoxic responses.
Innovation Solution
The development of self-assembled protein particles using divalent cations, which induce both innate and adaptive immune responses, including specific B cells, T helper cells, and cytotoxic T cells, without the need for additional adjuvants, with particle sizes ranging from 50 to 4000 nm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If soluble proteins are used as vaccine antigens, then the vaccine formulation is simple and easy to manufacture, but the ability to induce both innate and adaptive immune responses is limited
Solution Approach 1:
The patent changes the physical state parameter of the protein antigen from soluble to particulate form. The protein is formulated as nanoparticles or microparticles (50-4000 nm), which fundamentally alters its interaction with the immune system while maintaining ease of manufacture through self-assembly methods
Solution Approach 2:
The invention creates composite particulate structures where proteins self-assemble into nanoparticles or microparticles. These composite particles combine the simplicity of protein-based vaccines with the immune-stimulating properties of particulate materials, achieving both ease of manufacture and reliable immune response induction
2Ease of manufacture
If soluble proteins are used as vaccine antigens, then the manufacturing process is simple, but the induction of CD8-T cell cytotoxic responses is insufficient
Solution Approach 1:
The patent changes the size parameter of the protein from molecular scale to nanoparticle/microparticle scale (50-4000 nm). This parameter change enables the particles to be effectively taken up by antigen-presenting cells and processed to induce CD8-T cell cytotoxic responses while maintaining simple manufacturing through self-assembly
3Reliability
If additional adjuvants are added to enhance immune response, then the immune response is strengthened, but the device complexity and formulation complexity increase
Solution Approach 1:
The patent employs self-assembling protein particles that inherently possess immunostimulatory properties. The particles self-assemble into functional nanoscale structures that automatically provide adjuvant-like effects without requiring external adjuvant additives, thus strengthening immune response while avoiding formulation complexity
Solution Approach 2:
The protein-based nanoparticles serve multiple functions simultaneously: they act as the antigen, provide structural framework, offer surface area for immune recognition, and provide inherent adjuvant activity. This multi-functionality eliminates the need for separate adjuvant components, reducing overall formulation complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These protein-only particles elicit robust immune responses, including antibody production and cytotoxic T cell activation, providing a new paradigm for immunization by inducing both arms of the immune system effectively and safely.
Implementation Method 1
particles formed of self-assembled proteins by means of divalent cations
Data Source
AI summary
An immunogenic composition including a particle with a particular hydrodynamic diameter, the particle comprising self-assembled protein and/or peptide molecules and one or more salts of divalent cations. The immunogenic composition can be used in various vaccines and in the prevention and/or treatment of diseases.